Bull, Bear & Beyond – AFT Pharmaceuticals: executive interview

AFT Pharmaceuticals (NZX: AFT) is a commercial-stage specialty pharma company with strong roots in Australasia, its own salesforce and a growing global presence through licensing and distribution agreements. The product portfolio is a mix of own-branded, generic and in-licensed products across various therapeutic areas, targeting the over-the-counter, hospital and prescription segments. AFT is profitable and dividend distributing, with NZ$200m in revenues expected to be achieved in CY24 and a rolling target of NZ$300m.

In this interview, we speak to AFT co-founder and CEO, Dr Hartley Atkinson, about the company’s business strategy and key growth drivers as well as some of the exciting developments investors should look forward to in the next 12–18 months.

Listen on your preferred podcast player below:

Spotify
YouTube
Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets. These discussions offer unique insight into how leaders navigate challenges, drive growth, and deliver long-term value for stakeholders.